8 min read

EverHint Signal — EMA10 × EMA30 Crossover — December 29, 2025

44 crossover signals today: 18 buy signals led by Warner Music and Dutch Bros, 26 sell signals topped by GRAIL and Ultragenyx. Markets mixed with VIX at 14.2 as year-end trading winds down.

What This Signal Is (Quick)

The EMA10 × EMA30 Crossover strategy is an experimental scanner that tracks fresh momentum shifts between two exponential moving averages. When the 10-day EMA crosses above the 30-day EMA, it generates a buy signal—indicating short-term momentum is overtaking the medium-term trend. When the 10-day EMA crosses below the 30-day EMA, it generates a sell signal—suggesting momentum is weakening.

This is a dual-signal strategy. Unlike pure buy-signal scanners, this one tracks both bullish and bearish crossovers, giving you a complete picture of momentum shifts across the market. The EMA10 × EMA30 setup is more responsive than slower combinations like EMA10 × SMA50, generating more frequent signals but also carrying higher whipsaw risk in choppy markets.

Ideal for swing traders with 1-4 week holding periods. This is experimental. Use for educational purposes and backtesting only.


How We Ranked Today (Reader Version)

Today's 44 signals are ranked by RSI(14), with the most extreme readings first. For buy signals, lower RSI suggests more oversold conditions—potentially better entry points. For sell signals, higher RSI suggests more overbought conditions—potentially better exit points.

We've overlaid three additional data layers:

  • Insider Net (USD): Net insider buying (purchases minus sales) over the last 90 days. Positive = insiders accumulating, negative = distributing. We only count open-market purchases (P) and sales (S)—no awards, exercises, or tax transactions.
  • Days → Earnings: Calendar days until the next earnings report. Closer dates mean higher event risk (volatility).
  • Analyst Coverage: Number of analysts covering the stock and consensus estimates (where available).

These signals are for educational use and backtesting. Not financial advice. See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/


📈 Buy-Side Signals (18 Total)

Rank Ticker Company Sector Last ($) RSI(14) Insider Net (USD) Days → Earnings Market Cap
1 AEG Aegon Ltd. Financial Services 7.76 44.82 60 (amc) $12.4B
2 SBLK Star Bulk Carriers Corp. Industrials 19.71 45.74 50 (amc) $2.3B
3 CRK Comstock Resources, Inc. Energy 24.13 46.21 50 (amc) $7.1B
4 CTRA Coterra Energy Inc. Energy 26.20 46.08 56 (amc) $19.9B
5 SU Suncor Energy Inc. Energy 43.73 47.31 37 (bmo) $52.5B
6 NXT Nextpower Inc. Technology 90.21 51.01 29 (bmo) $13.4B
7 WEX WEX Inc. Technology 152.81 53.45 -$74,792 37 (bmo) $5.2B
8 AES The AES Corporation Utilities 14.13 56.72 60 (amc) $10.1B
9 AMCR Amcor plc Consumer Cyclical 8.45 60.20 36 (bmo) $19.5B
10 TLN Talen Energy Corporation Utilities 380.27 61.22 59 (bmo) $17.4B
11 BHVN Biohaven Ltd. Healthcare 11.54 62.69 +$30,470,765 63 (bmo) $1.2B
12 EBAY eBay Inc. Consumer Cyclical 87.74 62.87 58 (amc) $39.7B
13 CI Cigna Corporation Healthcare 276.01 71.16 31 (bmo) $73.7B
14 PCG Pacific Gas & Electric Co. Utilities 15.99 72.83 45 (bmo) $35.1B
15 BRX Brixmor Property Group Inc. Real Estate 26.36 76.66 42 (amc) $8.1B
16 VRRM Verra Mobility Corporation Industrials 22.74 78.14 59 (amc) $3.6B
17 BROS Dutch Bros Inc. Consumer Cyclical 64.48 79.99 -$21,345,152 44 (amc) $11.2B
18 WMG Warner Music Group Corp. Communication Services 30.22 86.72 +$998,383 38 (bmo) $15.8B

📉 Sell-Side Signals (26 Total)

Rank Ticker Company Sector Last ($) RSI(14) Insider Net (USD) Days → Earnings Market Cap
1 OCUL Ocular Therapeutix, Inc. Healthcare 12.30 12.28 63 (bmo) $2.1B
2 BXSL Blackstone Secured Lending Fund Financial Services 27.12 23.38 58 (bmo) $6.3B
3 BKH Black Hills Corporation Utilities 69.75 29.43 37 (bmo) $5.0B
4 GRAL GRAIL, Inc. Healthcare 87.88 30.36 52 (amc) $3.1B
5 BOOT Boot Barn Holdings, Inc. Consumer Cyclical 178.38 32.29 31 (bmo) $5.5B
6 IESC IES Holdings, Inc. Industrials 397.87 34.77 -$1,042,160 36 (bmo) $7.9B
7 PCOR Procore Technologies, Inc. Technology 74.13 34.52 -$2,684,966 45 (amc) $11.1B
8 WCC WESCO International, Inc. Industrials 251.88 36.25 -$654,104 43 (bmo) $12.3B
9 WYNN Wynn Resorts, Limited Consumer Cyclical 122.27 36.27 -$425,000 45 (amc) $12.7B
10 WRD WeRide Inc. Technology 8.66 36.64 74 (bmo) $2.5B
11 PRCT PROCEPT BioRobotics Corporation Healthcare 32.15 41.31 57 (amc) $1.8B
12 LMND Lemonade, Inc. Financial Services 71.32 42.37 57 (bmo) $5.2B
13 LPX Louisiana-Pacific Corporation Industrials 81.92 42.12 51 (bmo) $5.7B
14 CYTK Cytokinetics, Incorporated Healthcare 61.79 44.62 -$2,196,051 59 (amc) $7.4B
15 BIRK Birkenstock Holding plc Consumer Cyclical 41.20 45.65 $7.7B
16 RCAT Red Cat Holdings, Inc. Technology 7.81 46.55 $700.4M
17 GPI Group 1 Automotive, Inc. Consumer Cyclical 402.99 47.98 37 (bmo) $5.2B
18 SEZL Sezzle Inc. Financial Services 68.06 50.48 57 (amc) $2.3B
19 POET POET Technologies Inc. Technology 6.54 52.96 $861.8M
20 FSS Federal Signal Corporation Industrials 111.54 53.85 58 (bmo) $6.8B
21 OC Owens Corning Industrials 112.94 54.55 56 (bmo) $9.3B
22 PSIX Power Solutions International, Inc. Industrials 62.47 55.11 84 (bmo) $1.4B
23 ARMK Aramark Industrials 37.36 57.67 36 (bmo) $9.8B
24 GIS General Mills, Inc. Consumer Defensive 46.92 57.86 78 (bmo) $25.6B
25 RARE Ultragenyx Pharmaceutical Inc. Healthcare 19.72 11.86 45 (amc) $1.9B
26

Field Notes

RSI(14) Interpretation: Buy signals range from 44.82 (AEG) to 86.72 (WMG). The lower-RSI names like AEG, SBLK, and the energy trio (CRK, CTRA, SU) are in neutral-to-slightly-oversold territory—potentially offering better risk/reward if the crossover holds. WMG and BROS are overbought (RSI >70), suggesting momentum is strong but entry risk is higher.

Sell signals range from 12.28 (OCUL) to 57.86 (GIS). OCUL and RARE show extreme oversold readings despite bearish crossovers—these could be falling knives or potential reversal candidates. BXSL, BKH, and GRAL are deeply oversold, which might attract contrarian buyers. The mid-range sell signals (ARMK, GIS, FSS) are more neutral.

Insider Activity Highlights:

  • BHVN (Buy): Massive insider buying—$30.5M net purchases in November. CEO Vlad Coric bought $2.5M, director John Childs bought $25M, and director Gregory Bailey bought $3M. All at $7.50/share. Stock now at $11.54. Strong insider conviction.
  • WMG (Buy): Director Valentin Blavatnik purchased $998,383 (35,810 shares at $27.88) on Dec 2. Stock now at $30.22.
  • BROS (Sell): Heavy insider selling—$21.3M net sales. Executive Chairman Travis Boersma and affiliated entities sold large blocks in late November.
  • PCOR (Sell): -$2.7M net insider selling. Chairman Tooey Courtemanche sold $21.6M (300,000 shares at $71.91) on Nov 19.
  • CYTK (Sell): -$2.2M net insider selling from multiple directors and officers.
  • IESC (Sell): -$1.0M net insider selling from Executive Chairman Jeffrey Gendell.
  • WCC (Sell): -$654K net insider selling from EVP Diane Lazzaris.
  • WEX (Buy): -$74,792 net insider selling (small amount).

Earnings Proximity: Most signals are in the 36-63 day range—well outside the high-volatility 7-day window. NXT (29 days), CI (31 days), BOOT (31 days), and AMCR (36 days) are the closest to earnings. PSIX (84 days) and GIS (78 days) are the furthest out.

Sector Breakdown:

  • Buy signals: Energy (3), Utilities (3), Consumer Cyclical (3), Healthcare (2), Technology (2), Financial Services (1), Industrials (1), Real Estate (1), Communication Services (1)
  • Sell signals: Industrials (7), Healthcare (5), Consumer Cyclical (4), Technology (4), Financial Services (3), Utilities (1), Consumer Defensive (1)

Energy and Utilities dominate buy signals—potential sector rotation into defensive/value plays. Industrials dominate sell signals—momentum weakening in cyclical names.

Recent News Highlights:

Buy Signals:

  • BHVN: Stock dropped 16% after-hours Dec 26 on failed Phase 2 depression drug trial. BHV-7000 missed primary endpoint for major depressive disorder. Despite this, massive insider buying in November suggests long-term conviction in other pipeline assets.
  • BROS: Seeking Alpha article (Dec 28) calls it "one of my favorite non-tech growth plays." Targets 160 new stores in 2025, expanding food menu. Another article (Dec 25) notes 243% revenue growth since 2021 IPO.
  • AES: Zacks (Dec 26) highlights strong momentum score. Another article (Dec 29) lists AES as a value stock to buy as rate cuts reshape markets.
  • CTRA: Seeking Alpha (Dec 23) projects potential for over $2B in 2026 free cash flow. Q3 production beat guidance.
  • CI: Multiple institutional buying reports. Pacer Advisors increased holdings by 41.1%.
  • WMG: Director Valentin Blavatnik purchased nearly $1M in shares on Dec 2.
  • EBAY: Earnings report due Feb 25 (58 days out).

Sell Signals:

  • CYTK: FDA approved MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy on Dec 22. Stock up on approval, but now crossing below EMA30. Management targets >50% preference share vs. competitor CAMZYOS. Insider selling continues despite approval.
  • BOOT: Zacks (Dec 24) article: "4 Retail Apparel Stocks Poised to Lead Consumer Rally in 2026." Consensus rating: Moderate Buy from 17 analysts.
  • BKH: Seeking Alpha (Dec 24): "Buy This Dividend King With Data Center Catalysts." 54 consecutive years of dividend increases, 3.9% yield. Benefits from data center demand.
  • PCOR: Founder Tooey Courtemanche to deliver keynote at Building for Tomorrow Summit. Heavy insider selling in November.
  • GRAL: Illumina sold 1M shares at $79.85 on Nov 17 (10% owner reducing stake).
  • SEZL: Motley Fool (Dec 22): "My Top 2 Financial Stocks to Buy in 2026." Continues to gain market share in BNPL industry.
  • BROS: Also appears in sell signals due to heavy insider selling, despite positive growth narrative.

Vlad's Take (EverHint)

Markets ended the year-end week in mixed fashion. S&P 500 +0.03%, Nasdaq +0.25%, Dow -0.36%. Tech showed relative strength while blue chips lagged—classic sector rotation behavior. Small-caps underperformed (Russell 2000 -0.26%), suggesting some defensive positioning ahead of the new year. VIX closed at 14.2, down from 14.69—low volatility, complacent market. 10-year Treasury yield flat at 4.116%. Bitcoin -0.78% to $87,191, Ethereum -0.54% to $2,933—crypto consolidating after recent moves. Overall: Cautiously bullish environment with low volatility and light holiday volume.

Given this backdrop, today's 44 crossover signals offer a mixed bag. The buy-side energy cluster (CRK, CTRA, SU) is interesting—energy has been unloved in 2025, and these crossovers could signal early rotation into value. All three are below their 200-day SMAs, so this is a "show me" setup. Watch for follow-through. The utilities trio (AES, TLN, PCG) also fits the defensive rotation theme. PCG is particularly interesting—trading right at its 200-day SMA ($15.69 vs. $15.99), strong RSI (72.83), and benefiting from California's data center buildout.

BHVN is the wildcard. Massive insider buying at $7.50 in November, stock now at $11.54 despite the Dec 26 trial failure. Insiders clearly see value in the broader pipeline. But this is high-risk biotech—only for those with strong stomachs.

On the sell side, the industrial cluster (IESC, WCC, FSS, OC, LPX, PSIX, ARMK) is notable. Seven industrials crossing below EMA30 suggests cyclical weakness. IESC, WCC, and PCOR all show significant insider selling, which reinforces the bearish signal. CYTK is the most interesting sell—FDA approval on Dec 22, but insiders have been selling for months. The approval is priced in, and now momentum is rolling over.

BROS appears on both lists due to timing—it's a buy signal technically (EMA10 crossed above EMA30), but insider selling is heavy ($21.3M). This creates a conflict. The technical setup says "buy," but insiders are distributing. I'd wait for insider activity to stabilize before entering.

Strategy for these setups: Given the low VIX and year-end positioning, expect choppy action in the first week of January. Don't chase the buy signals on day one—wait for volume confirmation. For sell signals, consider these as exit points rather than short entries unless you're an active trader. The industrial weakness is worth monitoring—if it spreads to other cyclical sectors, it could signal a broader market rotation.

One more thing: We're in the final trading days of 2025. Volume will be light, spreads may widen, and institutional participation is minimal. These signals may not get the follow-through they deserve until the first full week of January. Patience is key. Use this time to build watchlists, not to force trades.


🎯 A simple like, share, or subscribe helps this channel reach more traders who follow data, not noise.


Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/